CJC-1295: Sustained Growth Hormone for Body Composition
CJC-1295 takes an anabolic approach to body composition — building up the body's own GH production:
GHRH Analogue: CJC-1295 mimics Growth Hormone Releasing Hormone but with a significantly extended half-life. This produces sustained GH elevation rather than a single pulse, maximising exposure to GH's beneficial effects.
IGF-1 Amplification: Sustained GH release stimulates hepatic IGF-1 production, which mediates GH's anabolic effects — muscle protein synthesis, fat oxidation, and bone mineralisation.
Body Composition: CJC-1295 shifts body composition towards lean mass by supporting protein synthesis (muscle building) and lipolysis (fat breakdown) simultaneously. This is a fundamentally different approach from caloric restriction or appetite suppression.
Additional Benefits: Deep sleep support, enhanced recovery between training sessions, and metabolic optimisation through sustained GH pathways.
ORYN Format: €109 for a 30-day pen with 5mg pharmaceutical-grade CJC-1295.
Semaglutide vs Tirzepatide: Why ORYN Chose Tirzepatide
Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist widely known for weight management. ORYN offers Tirzepatide instead, and the science supports this choice:
Semaglutide (GLP-1 Only): Activates GLP-1 receptors to suppress appetite, slow gastric emptying, and improve insulin sensitivity. Clinical trials (STEP-1) showed 14.9% weight loss at 68 weeks.
Tirzepatide (GIP + GLP-1): Activates both GIP and GLP-1 receptors. The additional GIP pathway enhances fat metabolism in adipose tissue. SURPASS-2 showed Tirzepatide outperformed Semaglutide at all dose levels, with SURMOUNT-1 showing up to 20.9% weight loss.
Why Tirzepatide Wins: Dual receptor action produces greater efficacy with potentially fewer GI side effects at equivalent doses. For metabolic research, Tirzepatide represents the current state of the art.
ORYN Tirzepatide Options: Standard pen (10mg, €169) for daily precision dosing, or MediT Pen (40mg, €249) for weekly administration.
CJC-1295 or Metabolic Peptides: Which Approach?
The choice between CJC-1295 and metabolic peptides depends on your research goals:
Choose CJC-1295 if: - Your focus is growth hormone biology and its downstream effects - You want to improve body composition via anabolic pathways (building lean mass) - Recovery, sleep quality, and tissue repair are research endpoints - You are studying GH/IGF-1 axis modulation - Budget is a factor (€109 is the most affordable option)
Choose Tirzepatide (or Semaglutide) if: - Weight management is the primary research endpoint - Appetite regulation and caloric intake reduction are being studied - Metabolic syndrome, insulin sensitivity, or glucose regulation is relevant - You want the most clinically validated weight loss approach - Your protocol requires an incretin-based mechanism
Key Distinction: CJC-1295 builds the body up through GH (anabolic). Metabolic peptides primarily reduce body weight through appetite suppression and metabolic regulation (catabolic/regulatory). These are fundamentally different strategies.
